Search the Newsreel

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven

Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund …

Compañía de Minas Buenaventura y su nueva prioridad en pleno rally de metales

Compañía de Minas Buenaventura is shifting its focus to exploration over acquisitions due to record high metal prices, increasing its exploration budget by 30%. The company plans to maintain its CAPEX between US$385 million and US$415 million but will accelerate prospection and reevaluate mature …

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, …

Buenaventura (BVN) Stock Could Be Cheap Again On Earnings Value

Upgrade: Analysts Just Made A Massive Increase To Their AvenuesAI Limited (NSE:CCAVENUE) Forecasts

Compañía De Minas BuenaventuraA (BVN) Reports Stronger Earnings, Is The 8% Undervaluation Still Real?

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader …

Biohaven Pharma stock price target raised to $23 by RBC Capital

RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by …

Earnings call transcript: AvenuesAI posts strong Q1 2027 growth, shares fall

AvenuesAI Q1 PAT rises 45 percent; Company positions Rediff, US Payments and AI as next growth engines

AvenuesAI revenue surges 109% in Q1FY27; Board approves Nueromind merger

AvenuesAI Q1 Results: Revenue surges 109% YoY, PAT up 45%

CCAVENUE: Q1 FY27 revenue up 109% YoY, PAT up 45%, with major AI and capital structure initiatives approved

Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity

Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable …

Compañía de Minas Buenaventura (BVN) Is Up 13.5% After Strongly Improved Q2 2026 Profitability Reported

Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an …

Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. …

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving …

Buenaventura Mining Company Inc (BVN) stock price, news, quote and history

This page provides comprehensive financial information for Compañía de Minas Buenaventura S.A.A. (BVN), including its current stock price, historical data, performance overview, and analyst insights. The company engages in the exploration, development, and operation of various mines in Peru and internationally, focusing on gold, …

Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending

Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available …

Biohaven earnings set to show cash burn ahead of epilepsy data

Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline …

Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Understanding Momentum Shifts in (BHVN)

This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for …

Buenaventura (NYSE:BVN): A Fitting Pick for Affordable Growth Investors

Buenaventura Mining (NYSE:BVN) Stock Rating Lowered by Wall Street Zen

Friday's ETF with Unusual Volume: JEMA

The JPMorgan ActiveBuilders Emerging Markets Equity ETF is seeing unusually high volume in afternoon trading Friday, with over 503,000 shares traded versus three month average volume of about 136,000. Shares of JEMA were up about 0.2% on the day. Components of that ETF with …

See How Compania de Minas Buenaventura Ranks Among Analysts' Top Metals Picks

A study of analyst recommendations at the major brokerages shows that Compania de Minas Buenaventura S.A. (Symbol: BVN) is the #49 broker analyst pick, on average, out of the 50 stocks making up the Metals Channel Global Mining Titans Index, according to Metals Channel. …

Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026

Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. …

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it …

Biohaven Ltd. (BHVN) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics. The company, a biopharmaceutical firm, focuses on treatments for immunology, neuroscience, and oncology, with several drug candidates in various clinical …

Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?

Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of …

Price to sales forward of Cavendish plc – LSE:CAV